bimekizumab,adalimumab
ucb pharmaceuticals,abbvie
[' psa']
bkz showed clinically meaningful improvements in efficacy outcomes in bdmard-na ve psa pts at wk 16 through wk 52. no new safety signals. abs l02 #acr22 
Passionately curious rheumatologist, world traveler, wife, mother, sister, daughter, friend, dog lover. Believer in scientific method & evidence based medicine.